Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| LIV-1 mAb - 01 | PCC | Solid Tumor | Colorectal cancer,Breast cancer |
Anti-LIV-1 mAb captured on CM5 chip via anti-human IgG Fc antibody can bind Human LIV-1, His Tag (Cat. No. LV1-H5223) with an affinity constant of 5.24 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ladiratuzumab vedotin | MK6440; MK-6440; SGN-LIV1A | Phase 2 Clinical | Seattle Genetics Inc, Merck Sharp & Dohme Corp | Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
This web search service is supported by Google Inc.
A-Z
